Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Press Release:
CDEX to Attend Health Connect Partners 2011 Fall Hospital Pharmacy Conference
ValiMed G4 Medication Validation System Demonstrated at Event
tweet0EmailPrintCompanies:CDEX INC CL A Related Quotes
Symbol Price Change
CEXI.OB 0.0380 0.00
{"s" : "cexi.ob","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""} Press Release Source: CDEX Inc. On Tuesday September 27, 2011, 9:00 am
TUCSON, AZ--(Marketwire -09/27/11)- CDEX Inc. (OTC.BB: CEXI.OB - News), a leading developer of chemical detection products, using patented technologies for use in healthcare, safety and security markets, will demonstrate the capabilities of the ValiMed™ G4 drug validation system at the 2011 Health Connect Partners Fall Hospital Pharmacy Conference. The conference is taking place September 26-28, 2011 at the Arizona Biltmore in Phoenix, Ariz.
The Hospital Pharmacy Conference connects healthcare providers and suppliers through a selection of educational meetings and conferences. The conference is known for its large scale Reverse Expo with hospital pharmacy-hosted booths. Suppliers have a unique opportunity to gain a deeper understanding of their clients' needs and preferences.
Senior members of the CDEX team will be attending the semi-annual event which connects healthcare industry leaders and provides education on the current state of hospital pharmacy business and legislation.
"Attending the Health Connect Partners conference is a vital part of our continued efforts to market our new ValiMed G4 directly to the key decision makers in the healthcare pharmacy system. The conference provides an optimum environment to build and enhance relationships with top hospital and health system pharmacy executives from across the US. The event is a great platform to launch our VG4 and further build our pipeline of interested agencies. We expect to deliver our first VG4 unit ahead of schedule," stated Jeff Brumfield, chairman and chief executive officer of CDEX.
The ValiMed G4 drug validation system helps healthcare providers ensure patient safety and control costs by reducing medication errors. The patented detection process identifies drug strengths and volume-by-weight in real-time, validating proper dose, diluents and concentration of high-risk compounded medications and treatment solutions. The VG4 device will help healthcare facilities comply with Joint Commission compliance requirements and USP 797 guidelines for compounding sterile preparations (CSPs), and will integrate with electronic medical record (EMR) platforms.
About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare, safety and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and pharmacy returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched. To learn more about CDEX please visit: www.cdex-inc.com.
Safe Harbor Statement
Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "believes," "should," "intends," and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.
Contact:
Company contact: Jeff Brumfield (520) 745-5172 Email Contact Sales contact:John McConnell(615) 218-7993Email Contact
hjc64:
Agree with you wholeheartily. Pennstreet says nothing of substance. The only takeaway you can get from Pennstreet's posts is that CDEX hasn't gone under yet and this go around they're really trying.
Hey Crow & Diddy:
Does this quote from Amanita sound like a "guess"????????
"CDEX selling VMED parts on Ebay"
Didn't come close to backing up that statement, now did your new pal Amanita?
Amanita:
Then your posting is worthless and irresponsible-your credibility lost-you should be ignored by all.
Please do tell as to how you link these sales as being made by CDEX?
Pennstreet:
You have the pulse of CDEX. LOL
What say you about JB's BK fiasco...his honesty...his ability to lead...his credibility in the marketplace?
Where are those additional 200 million shares going? As far as I can ascertain JB no longer has any shares in the Company! You think JB and cohorts might scarf up some or all of those shares?
If you're going to post a response with your usual generalities, no reply is necessary.
JB has some explaining to do to CDEX shareholders. Come out, come out, wherever you are JB.
It takes some real cahoones (sp) to ask for an additional 200 million shares in light of recent developments.
Crow:
Every once in awhile your posts ring true. This was one of them.
Crow:
Did JB go BK individually or one of his entities? If not JB personally, his shares would seem to have been safe.
Crow:
It's posts like the last one that you lose any hope that your words will be taken as credible. Please subtantiate your allegation with factual detail, instead of a pure off the wall assumption that because McCommon signs some filings (after all, he is the CFO), he is the real CEO.
MP is out--lucky he left in the middle of the night-or be tarred and feathered. Gemini did give him multiple reprieves, but JB finally won out.
MP is simply a disgraced large shareholder--with less shares than JB, I might add.
If MP had anything to do with or control of the Company, directly or indirectly, JB, Poteet, Fogelsong and others would not have touched CDEX with a ten foot pole.
Slow down Crow and think before you post.
Diddy:
It's all meaningless drivel. Makes like he's in the know, but the bottom line is that I surely do not look to his posts for guidance or feel any more optimistic due to his posting. Not so sure that Pennstreet is Robert Stewart. I'm betting Jeff Ammon.
Crow3:
That IHUB trade page is totally inaccurate. I say that with first hand knowledge. In the past I have bought at the ask and they reported it as a sell. I have checked this site against both the Etrade and Scottrade streamer and it usually is of in characterizing a trade as a buy or sell or question mark.
Accumulation:
You cannot screw up for over a decade in the tech. world and then hope to turn it around--especially without money or product.
Reality Finally Sinks In:
CEXI days are numbered. Horrible partner (Gemini); no money (crooks raided the coffers for years); no new money; unreliable products that are no longer "state of the art" or essential-assuming they ever were; figurehead directors; and the largest shareholder running the Company not based on his resume, but simply because he has the most to lose.
The next quarterly report will be the icing on the cake. The Company and apologists will have run out of excuses and will no longer have the ballz to say 'wait for the next quarterly report".
Keeping it REAL:
I have little doubt that present management is honest and is working diligently.
Nor do I question the past accomplishments (outside of LOCH and CDEX)or diligence of Dr. Poteet.
However, my research indicates that the CDEX products, even if working for the intention desired, are dated and rather one-dimensional. I fear that Dr. Poteet's "science" is "old". There are colleges and private companies and whiz kid scientists that have passed and gone beyond the CDEX products in range of use, speed and RELIABILITY.
In essence, I think the CDEX products would have been innovative in 2005, but are passe in 2011.
And let's not forget about the lack of funding CDEX must face day in and day out.
No doubt the BOD has been upgraded, but do they have the ammo to work with? Hate to use a sports analogy, but would the Packers have won with Jemarcus Russell at QB?
200 Million More Shares:
For those of you who think I'm all wet concerning the additional 200 million shares being proposed and what it will do to your investment, this is what the shamelessly pro-CDEX poster, Pennstreet, is saying on the IHub Board:
"You are absolutely right, once the increase in shares are voted for, the company stock price may go to 1 cent or lower. Take a load off and let it go."
Now we know we (public shareholders) won't be getting any of those 200 million shares, but do you think for a moment that JB, MP, the directors and certain insiders won't be scarfing up some of those shares to keep or increase their percentage interest in the Company????????????????????????????????????????????
JB should be speaking to this issue, but it's as plain day why he remains silent...how do you tell the shareholders that there will no dilution for him and select others?????????????????????????
Based on his silence, I'm not sure where JB stands on anything!!!!!!!!!!!! Does anyone have a clue?
Can anyone make an argument that the selling rampage IS a vote of confidence for JB, his leadership and where he is taking this Company ????
Pennstreet: (Who Is Not Robert Stewart)
You place way too much importance in your posts. In the eyes of many you are just JB's whipping boy; not credible; and touting as pay back for the renumeration you have or will receive in shares or otherwise, for your efforts in getting JB in and MP out. I gotta laugh-"some" selling started when you began posting about PMR. Right-the investing world waits with great anticipation for the next utterance from Pennstreet. "SOME SELLING". LOL
Here are just some of the reasons people are dumping this POS.
Most going on year 5 10,12 or more. As for me, it's year 12 and I still hold a good deal of this POS. Doesn't say much for my judgment. Rather be with a Company that has bona fide sales and isn't beating the bushes for investors just to stay alive. The CDEX tech is mediocre at best, has never performed consistently in the field and what's the big deal about getting back the "science" team that couldn't cut it for 11 plus years. Funny how those distinguished "scientists" never found another job after they left CDEX. Surely some company would have scooped up these potential Nobel Prize recipients. Doesn't sit right with me that a Company that doesn't even have a marketable product on its own is going to be adding 200 million shares to hunt out a company that might have a product. That's called desperation and brass balls. Might have well as done it by buying up a shell corp. The dilution may well render CDEX shareholder's investment virtually worthless.
You could have the last 4 Presidents on the BOD and that wouldn't change the precarious position this Company is in!!!!!!!!!!
Time to cut some of my losses and realize my mistake. For virtually the same pps. I can have ownership in a Company on the upswing, with legitimate sales and proven tech IN THE FIELD.
This is scary:
CDEX, trading at .035 by .036 had app. 25,000 legitimate buys and app. 500,000 legitimate sells today!!!!!!!!!!!!!!!
ESNR, trading at .045 by .06 had app. 288,000 legitimate buys and ZERO legitimate sells!!!
PS:
JB may be the most well intentioned person in the universe, but the BBoyz and MP likely have brought this Company to the point of no return.
Crow3:
Bid down to .0425. There's your answer.
Two stocks at an intersection, heading in different directions:
CEXI - shares sold today 220,952 all at .05 or .051. NO BUYS.
ESNR - shares bought today 220,000 at .05. ONE SELL of 400 shares.
Not on the info in the pyblic domain:
I'm not privy to all the exciting things happening behind the scenes. But Atlanta lost in the playoffs leaving director Frank Wren time really jump start CDEX.
Sea Urchin:
The way this Company is headed, material news would be selling a ValiMed unit or someone investing $199.00.
Crow3:
Why buy? Pennstreet seems to think that the door still being barely open and the stock dropping on a weekly basis means good times ahead.
Material news must be disclosed. Therefore, one can assume that there is nothing positive to say, other than we're hanging on.
Very Interesting Re ESNR:
Putting 2 and 2 together.
Breath test for breast cancer-z-nose is detecting breast cancer in a couple of seconds!
"Breast cancer is one of the most common and one of the most treatable human malignancies. One in every ten women now develops breast cancer at some time in her life. Fortunately, there is now conclusive evidence that early detection with screening mammography can reduce mortality from the disease. But mammography is not without its own problems: many women find the required breast compression to be uncomfortable and even painful. Also, the test is comparatively expensive and generates a large number of false positive findings, resulting in needless anxiety and biopsies. There is a clinical need for an alternative method of screening for breast cancer which is at least equally accurate, but is less painful, less expensive, and free of potentially hazardous radiation."
"We performed a pilot study of a breath test for breast cancer at two New York hospitals, supported by a grant from the National Institutes of Health/National Cancer Institute. We found that breath markers of oxidative stress were altered in breast cancer, and provided an accurate new marker of the disease. The negative predictive value of the breath test was equivalent to a screening mammogram, indicating that a breath test might be used as a noninvasive screening test for breast cancer."
"A recent study at the University of Western Australia led to similar findings. In an article soon to appear in The Journal of Breath Research, we found that the breath test detected breast cancer with 83% accuracy, better than the reported accuracy of film or digital mammograpy."
PDF Document) Phillips M, Cataneo RN, Saunders C, Hope P, Schmitt P, and Wai J: Volatile biomarkers in the breath of women with breast cancer. Journal of Breath Research (Mar. 2, 2010).
"all VOC samples were collected at the Royal Perth Clinic and sent by express mail for analysis to the Breath Research Laboratory of Menssana Research Inc., Newark, NJ."
-------------------------------------------------------------
EST Announces Follow On Order From Menssana Research Inc.
NEWBURY PARK, Calif., Oct. 6, 2010 (GLOBE NEWSWIRE) -- Electronic Sensor Technology Inc. (Pink Sheets:ESNR - News), a leading provider of ultra-fast vapor analyzers, announced today that it had received an order for ten model 4200 instruments from Menssana Research Inc. Fort Lee New Jersey, the leading research company in the area of breath analysis.
"We are pleased to strengthen our association with Dr. Michael Philips and Menssana Research Inc. Dr. Philips is a pioneer in breath analysis and is the leading developer of advanced new breath tests for detection of diseases including: lung cancer, breast cancer, heart transplant rejection, ischemic heart disease, kidney disease, tuberculosis and diabetes mellitus," said William Wittmeyer, COO of EST, Inc.
Pennstreet:
Very Interesting Re ESNR:
Putting 2 and 2 together.
Breath test for breast cancer-z-nose is detecting breast cancer in a couple of seconds!
"Breast cancer is one of the most common and one of the most treatable human malignancies. One in every ten women now develops breast cancer at some time in her life. Fortunately, there is now conclusive evidence that early detection with screening mammography can reduce mortality from the disease. But mammography is not without its own problems: many women find the required breast compression to be uncomfortable and even painful. Also, the test is comparatively expensive and generates a large number of false positive findings, resulting in needless anxiety and biopsies. There is a clinical need for an alternative method of screening for breast cancer which is at least equally accurate, but is less painful, less expensive, and free of potentially hazardous radiation."
"We performed a pilot study of a breath test for breast cancer at two New York hospitals, supported by a grant from the National Institutes of Health/National Cancer Institute. We found that breath markers of oxidative stress were altered in breast cancer, and provided an accurate new marker of the disease. The negative predictive value of the breath test was equivalent to a screening mammogram, indicating that a breath test might be used as a noninvasive screening test for breast cancer."
"A recent study at the University of Western Australia led to similar findings. In an article soon to appear in The Journal of Breath Research, we found that the breath test detected breast cancer with 83% accuracy, better than the reported accuracy of film or digital mammograpy."
PDF Document) Phillips M, Cataneo RN, Saunders C, Hope P, Schmitt P, and Wai J: Volatile biomarkers in the breath of women with breast cancer. Journal of Breath Research (Mar. 2, 2010).
"all VOC samples were collected at the Royal Perth Clinic and sent by express mail for analysis to the Breath Research Laboratory of Menssana Research Inc., Newark, NJ."
-------------------------------------------------------------
EST Announces Follow On Order From Menssana Research Inc.
NEWBURY PARK, Calif., Oct. 6, 2010 (GLOBE NEWSWIRE) -- Electronic Sensor Technology Inc. (Pink Sheets:ESNR - News), a leading provider of ultra-fast vapor analyzers, announced today that it had received an order for ten model 4200 instruments from Menssana Research Inc. Fort Lee New Jersey, the leading research company in the area of breath analysis.
"We are pleased to strengthen our association with Dr. Michael Philips and Menssana Research Inc. Dr. Philips is a pioneer in breath analysis and is the leading developer of advanced new breath tests for detection of diseases including: lung cancer, breast cancer, heart transplant rejection, ischemic heart disease, kidney disease, tuberculosis and diabetes mellitus," said William Wittmeyer, COO of EST, Inc.
And finacially rewarded.
d4diddy:
I do not believe ---- -----is paid to post. He just worked closely with JB behind the scenes and is emotionally and financially invested in the new CDEX.
And maybe math would become easier!
Re Pennstreet:
Is not Robert Stewart. Too quick to respond at all times of the day. Even though Robert Stewart may have different monikers, the writing smacks of someone else.
If only Pennstreet wasn't so blindly devoted and, upon information and belief, being so handsomely rewarded. Perhaps then, we would read lucid and unbiased Pennstreet postings.
Pennstreet:
A math whiz, you're not. LOL If ESNR has a multiple of 2.48 of the number of shares of CDEX, then just figure that ESNR reverse splits by a factor of 2.48 to equal the number of shares CDEX has outstanding--then the stock price of ESNR would be 2.48 times greater than it is now. Apples to apples, ESNR trades higher than CDEX. Think about it.
Also, it matters not that the tech of ESNR is different from that of CDEX. The 2 companies are competing in more or less the same arenas-drug detection and analysis, explosive detection, etc. In fact, the ESNR technology, at least at this point, is more versatile and has a wider base of potential applications. Also, though it's not the fault of JB, CDEX has some fences to mend and tech to tweak, while ESNR appears to be in a fast forward mode.
I hold both stocks. I remain hopeful that JB can undo the mess created by MP and TS. And I certainly do not think that JB has anything to do with the past history of CDEX, other than being a screwed over shareholder like you and me. I do not know why CDEX retained McCommon. Maybe you can shed some light on this.
All:
Pennstreet may not be Robert Stewart. That's for you to JUDGE.
Pennstreet:
I have to laugh when you state that JB might need those extra 200 million shares to acquire other companies. You make it sound as is CDEX is like GE. How about developing one marketable application in your own company first?
I prefer not to give JB 200 million additional shares on the if come. If he needs additional shares in the future to purchase other companies, let him come to the shareholders at that time with a definitive proposal.
JB may have earned your undying loyalty, but he will only earn my faith and that of most common shareholders, when we see results.
Pennstreet:
I do not care if ESNR is on the pinks, blues or yellows. You conveniently ignore how ESNR compares to CDEX, where it matters the most.
First, you fail to take into account the shares outstanding re each company.
ESNR-Outstanding Shares- Shares Outstanding: 161.92M (source: Yahoo finance)
CEXI-Outstanding Shares- 65.24M (source: Yahoo finance)
Adjusting for the difference in shares outstanding, ESNR closed today at 3.9 cents by 4.5 cents-a CDEX equivalent of app. 10 cents by 12 cents!!!!!!!!!!!!!!!!!!!!!!!!!!!
Next, you cite some crapola from 1999 regarding ESNR and strangely (actually not so strangely) fail to recognize ESNR's last 3 PR's in the last 4 months, each of which exceed in accomplishment that of any CDEX PR. In case your memory has failed you, here they are:
PR #1:
Macedonia Purchases Six ZNOSE Model 4500 Portable Instruments
EmailPrint..Companies:Electronic Sensor Technology, Inc..Related
NEWBURY PARK, CA--(Marketwire - 05/25/10) - Electronic Sensor Technology Inc. (Pinksheets:ESNR - News), a leading provider of ultra-fast vapor analyzers, announced today that it had received an order for six instruments from the Government of Macedonia. Electronic Sensor Technology ZNOSE® model 4500 was selected over the competition in an open tender. This purchase was part of an ongoing program by the government of Macedonia to strengthen customs enforcement and border security.
The ZNOSE is a very versatile, ultra-fast Gas Chromatograph (GC). It is used to detect a variety of explosives including: TNT, RTX, C4 and TATP and nerve agents such as Sarin and Mustard Gas. The ZNOSE is flexible and easy to use; a change of software enables it to detect illegal drugs including cocaine, heroin, morphine and ecstasy. Similarly the same instrument can detect the adulteration of food products such as milk contaminated by melamine. The ZNOSE is currently being used for environmental, food/beverage, petro-chemical, life science and Homeland Security applications. For more information, please visit our website at www.estcal.com.
PR #:2
California Testing Authority LLC to Use zNOSE for Medical Cannabis Testing and Certification
NEWBURY PARK, Calif., Sept. 30, 2010 (GLOBE NEWSWIRE) -- Electronic Sensor Technology Inc. (Pink Sheets:ESNR - News) (EST) a leading provider of ultra-fast vapor analyzers, and California Testing Authority LLC, (CTA) an innovative leader in certification of cannabis for medical use, announced today that CTA will be EST's exclusive customer in California for the testing and certification of medical cannabis.
Using EST's zNOSE, CTA will conduct on-site testing of medical marijuana to insure the product is free from excessive molds, spores, insecticides and other pathogens. In addition, CTA will test the concentration of the three primary cannabinoids found in marijuana and provide the clinic with labels containing information on the strength and character of the marijuana being dispensed.
Cannabis or medical marijuana has been shown to have several well-documented beneficial effects. Among these are: the amelioration of nausea and vomiting, stimulation of hunger in chemotherapy and AIDS patients, lowered intraocular eye pressure (shown to be effective for treating glaucoma), as well as general analgesic effects (pain relief).
About Electronic Sensor Technology:
Founded in 1995, Electronic Sensor Technology has developed and patented a chemical vapor analysis process. EST's product provides near real-time analysis of gasses detecting volatile organic compounds in amounts as low as one part per trillion. EST's product has been shown to detect salmonella and e-coli contamination of food sources; chemical warfare agents such as Sarin and Agent Orange and Chemical pollutants in the environment.
About California Testing Authority
California Testing Authority LLC, (CTA) is a mobile certification and pre-screening service with a focus on the medical marijuana industry. The company offers mobile solutions for medical marijuana collectives to help meet and exceed local and state ordinance requirements. CTA provides mobile testing for potency levels of three primary cannabinoids found in marijuana: tetrohydrocannabiniol (THC), cannabidiol (CBD), and cannabiniol (CBN). In addition, safety testing is provided to detect above-average levels of molds and pathogens commonly found in medical marijuana. Our clients receive the benefit of detailed medicine bottle labels with on-the-spot printed results so collective owners can feel confident that patients are informed and public safety issues are addressed. These certified labels are rapidly becoming the standard for purchasing medical marijuana and we believe will soon become mandatory by law.
PR #3:
EST Announces Follow On Order From Menssana Research Inc.
NEWBURY PARK, Calif., Oct. 6, 2010 (GLOBE NEWSWIRE) -- Electronic Sensor Technology Inc. (Pink Sheets:ESNR - News), a leading provider of ultra-fast vapor analyzers, announced today that it had received an order for ten model 4200 instruments from Menssana Research Inc. Fort Lee New Jersey, the leading research company in the area of breath analysis.
"We are pleased to strengthen our association with Dr. Michael Philips and Menssana Research Inc. Dr. Philips is a pioneer in breath analysis and is the leading developer of advanced new breath tests for detection of diseases including: lung cancer, breast cancer, heart transplant rejection, ischemic heart disease, kidney disease, tuberculosis and diabetes mellitus," said William Wittmeyer, COO of EST, Inc.
The zNOSE is a very versatile, ultra-fast Gas Chromatograph (GC). It is used in medical research to detect trace amounts of volatile organic compounds found in human breath that are associated with specific diseases and the patients state of health. The zNOSE is also used to identify volatile organic compounds in trace amounts for detection of explosives, chemical warfare agents, illegal drugs and adulterants in foods. For more information, please visit our website at www.estcal.com.
About Electronic Sensor Technology:
Founded in 1995, Electronic Sensor Technology has developed and patented a chemical vapor analysis process. EST's product provides near real time analysis of gasses detecting volatile organic compounds in amounts as low as one part per trillion. EST's product has been shown to detect salmonella and e-coli contamination of food sources; chemical warfare agents such as Sarin and Agent Orange and Chemical pollutants in the environment.
•EST Announces Follow On Order From Menssana Research Inc.GlobeNewswire(Wed, Oct 6)
•California Testing Authority LLC to Use zNOSE for Medical Cannabis Testing and CertificationGlobeNewswire(Thu, Sep 30)
•Macedonia Purchases Six ZNOSE Model 4500 Portable InstrumentsMarketwire(Tue, May 25)
Pennstreet:
Thanks for the prompt and detailed reply.
An additional 30 to 40 million shares to secure new investment dollars seems reasonable. No doubt CDEX needs an influx of cash to stay in business. Based on your estimate of new shares needed, why ask for 200 million shares? You might answer that JB would not issue the excess shares--however, JB has no track record and has not earned the trust of shareholders, including myself. While 30 to 40 million additional shares without significant news may not be fatal, the issuance of 200 million additional shares without significant news would drive the pps. to shockingly low levels... like we are not already at a shockingly low level!
Also, JB must be saying something to potential pp shareholders to get them to invest in a Company that has been mismanaged, has been run by crooks, and whose "science" team has yet to hit paydirt in over a decade.
Yet JB remains totally silent with respect to the common shareholders. Not a word from him...no CEO Statement...no justification for asking for 200 million additional shares...nothing...nada. You suggest calling him. I suggest that he talk to ALL shareholders.
Finally, you state: " Mr. Brumfield would not be the least bit concerned about issuing himself more shares to maintain his percentage interest in Cdex, imho."
I believe you are making this statement to affirm that there is nothing wrong or illogical with JB issuing shares to himself to maintain his percentage interest in CDEX. I agree with that statement to a certain extent... that being with the proviso that he be mindful and diligent in not significantly reducing the percentage interest that I and other shareholders hold in CDEX. If he is not being a mench and is selfish in his attempt to maintain his interest, then he should be very concerned about issuing himself more shares.
So let me summarize: I do not know JB from Jack Sheet. I do know that he's requesting that 200 million more shares be authorized, where you acknowledge that he needs nowhere near that many new shares for new investors. Therefore, there exists the possibility that some or all of the excess shares will go to JB, who you also acknowledge would not be the least bit concerned about issuing more shares to himself to maintain his percentage interest in CDEX. I also know that JB is talking to potential private placement shareholders, but has yet to speak to his public shareholders. I also know that JB essentially took over by default, was not sought for his present position, and has no experience in running a public/tech corporation. I also know that the science team has yet come up with a successful, reliable, marketable product in over a decade and that not all this can be blamed on previous management.
So I remain wary, to say the least.
Pennstreet: Any Comments?
Reality Check:
When you think or rather pray for CDEX you think explosive detection, homeland security, and hazardous waste and drug identification...etc.
I am NOT touting another stock, but here's a sobering fact. There's a little company out of Newbury Park, CA. that trades at a measly 2-3 cents that is walking the walk and talking the talk and appears to be light years ahead of CDEX. Take a look at their last 3 press releases. It'll make you sick! JB, staff and the "science team" better be working double shifts, because even this barely on the radar company (ESNR)(EST) is making CDEX look pretty lame. Look at its last 3 PR's!!!!!!!!
--------------------------------------------------------------------
PR #1:
Macedonia Purchases Six ZNOSE Model 4500 Portable Instruments
EmailPrint..Companies:Electronic Sensor Technology, Inc..Related
NEWBURY PARK, CA--(Marketwire - 05/25/10) - Electronic Sensor Technology Inc. (Pinksheets:ESNR - News), a leading provider of ultra-fast vapor analyzers, announced today that it had received an order for six instruments from the Government of Macedonia. Electronic Sensor Technology ZNOSE® model 4500 was selected over the competition in an open tender. This purchase was part of an ongoing program by the government of Macedonia to strengthen customs enforcement and border security.
The ZNOSE is a very versatile, ultra-fast Gas Chromatograph (GC). It is used to detect a variety of explosives including: TNT, RTX, C4 and TATP and nerve agents such as Sarin and Mustard Gas. The ZNOSE is flexible and easy to use; a change of software enables it to detect illegal drugs including cocaine, heroin, morphine and ecstasy. Similarly the same instrument can detect the adulteration of food products such as milk contaminated by melamine. The ZNOSE is currently being used for environmental, food/beverage, petro-chemical, life science and Homeland Security applications. For more information, please visit our website at www.estcal.com.
PR #:2
California Testing Authority LLC to Use zNOSE for Medical Cannabis Testing and Certification
NEWBURY PARK, Calif., Sept. 30, 2010 (GLOBE NEWSWIRE) -- Electronic Sensor Technology Inc. (Pink Sheets:ESNR - News) (EST) a leading provider of ultra-fast vapor analyzers, and California Testing Authority LLC, (CTA) an innovative leader in certification of cannabis for medical use, announced today that CTA will be EST's exclusive customer in California for the testing and certification of medical cannabis.
Using EST's zNOSE, CTA will conduct on-site testing of medical marijuana to insure the product is free from excessive molds, spores, insecticides and other pathogens. In addition, CTA will test the concentration of the three primary cannabinoids found in marijuana and provide the clinic with labels containing information on the strength and character of the marijuana being dispensed.
Cannabis or medical marijuana has been shown to have several well-documented beneficial effects. Among these are: the amelioration of nausea and vomiting, stimulation of hunger in chemotherapy and AIDS patients, lowered intraocular eye pressure (shown to be effective for treating glaucoma), as well as general analgesic effects (pain relief).
About Electronic Sensor Technology:
Founded in 1995, Electronic Sensor Technology has developed and patented a chemical vapor analysis process. EST's product provides near real-time analysis of gasses detecting volatile organic compounds in amounts as low as one part per trillion. EST's product has been shown to detect salmonella and e-coli contamination of food sources; chemical warfare agents such as Sarin and Agent Orange and Chemical pollutants in the environment.
About California Testing Authority
California Testing Authority LLC, (CTA) is a mobile certification and pre-screening service with a focus on the medical marijuana industry. The company offers mobile solutions for medical marijuana collectives to help meet and exceed local and state ordinance requirements. CTA provides mobile testing for potency levels of three primary cannabinoids found in marijuana: tetrohydrocannabiniol (THC), cannabidiol (CBD), and cannabiniol (CBN). In addition, safety testing is provided to detect above-average levels of molds and pathogens commonly found in medical marijuana. Our clients receive the benefit of detailed medicine bottle labels with on-the-spot printed results so collective owners can feel confident that patients are informed and public safety issues are addressed. These certified labels are rapidly becoming the standard for purchasing medical marijuana and we believe will soon become mandatory by law.
PR #3:
EST Announces Follow On Order From Menssana Research Inc.
NEWBURY PARK, Calif., Oct. 6, 2010 (GLOBE NEWSWIRE) -- Electronic Sensor Technology Inc. (Pink Sheets:ESNR - News), a leading provider of ultra-fast vapor analyzers, announced today that it had received an order for ten model 4200 instruments from Menssana Research Inc. Fort Lee New Jersey, the leading research company in the area of breath analysis.
"We are pleased to strengthen our association with Dr. Michael Philips and Menssana Research Inc. Dr. Philips is a pioneer in breath analysis and is the leading developer of advanced new breath tests for detection of diseases including: lung cancer, breast cancer, heart transplant rejection, ischemic heart disease, kidney disease, tuberculosis and diabetes mellitus," said William Wittmeyer, COO of EST, Inc.
The zNOSE is a very versatile, ultra-fast Gas Chromatograph (GC). It is used in medical research to detect trace amounts of volatile organic compounds found in human breath that are associated with specific diseases and the patients state of health. The zNOSE is also used to identify volatile organic compounds in trace amounts for detection of explosives, chemical warfare agents, illegal drugs and adulterants in foods. For more information, please visit our website at www.estcal.com.
About Electronic Sensor Technology:
Founded in 1995, Electronic Sensor Technology has developed and patented a chemical vapor analysis process. EST's product provides near real time analysis of gasses detecting volatile organic compounds in amounts as low as one part per trillion. EST's product has been shown to detect salmonella and e-coli contamination of food sources; chemical warfare agents such as Sarin and Agent Orange and Chemical pollutants in the environment.
•EST Announces Follow On Order From Menssana Research Inc.GlobeNewswire(Wed, Oct 6)
•California Testing Authority LLC to Use zNOSE for Medical Cannabis Testing and CertificationGlobeNewswire(Thu, Sep 30)
•Macedonia Purchases Six ZNOSE Model 4500 Portable InstrumentsMarketwire(Tue, May 25)
Pennstreet: Any Comments?
Yes, it would be absolutely stupid to vote yes for an additional 2 million shares, without hearing from the CEO re the future.
As I stated before, there is no doubt that additional shares may be needed for new private placement investors to raise money. But the combination of dilution without significant news, will hurt the public shareholders. In this regard, if JB doesn't talk or show results, he will be no different from MP--a salesman of private placement shares.
I do not know if you visit the IHub Board, but there is a poster named Pennstreet that is almost certainly a pp investor (other posters claim that this is Robert Stewart).
From an October 8th post he states:
"Imho, two months is not going to be long enough to accomplish a new Technology. I would speculate next March or April."
That is one troubling statement!!!!!
First, the statement indicates that the addition of 200 million shares would come well before CDEX was able to market anything. So are we supposed to approve the additional shares in Nov. for something that might happen in March or April--6 months later????? Does JB take us for idiots? Do you think JB would issue more shares to himself to maintain his percentage interest in the Company????? No sheet.
Even more troubling is the fact that this statement indicates that CDEX is embarking on yet another NEW technology. And the beat goes on. What's that song? "Second verse, same as the first"
I'd say it's about time JB introduced himself to us shareholders. Don't you agree?
Crow3:
I have no idea whether MP orchestrated the derivative suit, but I can assure you he had nothing to do with the class action. The class action was commenced because the derivative suit was proceeding at a snails pace or not proceeding at all.